InvestorsHub Logo
Followers 165
Posts 13286
Boards Moderated 0
Alias Born 03/06/2011

Re: None

Wednesday, 02/22/2012 9:02:24 AM

Wednesday, February 22, 2012 9:02:24 AM

Post# of 923
2/22/2012 YM Biosciences recent weakness creates buying opportunity, says Wells Fargo
Wells Fargo believes that investors are failing to recognize the potential of YM's lead drug as a treatment for indications other than myelofibrosis. However, the firm believes that YM is undervalued based on the drug's potential in myelofibrosis alone, and it maintains an Outperform rating on the stock.

All my posts are my opinions. Investors should do there own DD!!